Bioxyne Ltd (BXN) Fair Value & Analysis
Consumer Defensive · AU · Market cap A$214M
Strengths
Risks
Fair value as of: Aug 13, 2026
From 24 valuation models · updated 12 days ago
Share price +10.7% over the past month.
A solid business, but trading 167% above our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (A$0.4335). The favourable scenario is already priced in.
- Solid but not exceptional quality (65/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (A$0.2380 to A$0.4335) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range A$0.0500 – A$1.05 · fair‑value band A$0.2380 – A$0.4335 · the A$0.9300 price screens above the A$0.3485 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Bioxyne Ltd (BXN) currently trades at A$0.9300, while our model-based Fair Value estimate is A$0.3485, implying the stock looks roughly 62.5% overvalued today. The Quality Score stands at 65/100 (solid quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Bioxyne Ltd generated revenue of A$48.0M at a net margin of 18.7%. Revenue grew 149.6% year over year. It earns a return on equity of 66.1%. The balance sheet holds a net cash position of A$6.1M. Fundamentals as of Aug 13, 2026
Our scenario range runs from A$0.2380 (bear case) to A$0.4335 (bull case); at A$0.9300, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Consumer Defensive peers we cover trades at -26% fair-value upside, at -63%, BXN screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings (A$0.9900) versus Asset-Based (A$0.0300). Highest evidence: Growth DCF (80).
Notify me when BXN reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 65 · Market factors (momentum, volatility) 75
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Bioxyne Limited, together with its subsidiaries, manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czechia, Switzerland, France, Germany, and Japan.
Full company description
Bioxyne Limited, together with its subsidiaries, manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czechia, Switzerland, France, Germany, and Japan. It operates through Pharmaceutical Manufacture and Wholesale Supply of Novel Medicines, Cannabis, Psilocybin, and MDMA; Manufacture and Distribution (Wholesale, Online, and Retail) of Consumer Health and Novel Food Products; and Wholesale of Patented Probiotics segments. The company offers active pharmaceutical ingredients and starting materials; plant-based food products, such as non-controlled cannabis extracts and cannabidiol; food grade mushroom extracts/psilocybin; medicinal and prescription cannabis products, including pastilles, vape, oral mucosal oils, flower, and suppositories; SL-NAD+ wafers; MDMA; white label manufactured wellness products; health and wellness supplements; and nootropic and skincare products. It also provides Lactobacillus fermentum VRI-003 PCC, a probiotic formulation for gastrointestinal health and immunity; Progastrim for gut and immune health; and proTract for atopic dermatitis. In addition, the company is involved in the contract manufacturing of final dose form products, including capsules, tablets, inhalables, oral solutions, and herbal preparations; import, export, manufacture, and supply of controlled drugs and medicinal products; research and development of formulations, products, and processes related to health, wellness, and medicine; and provision of telemedicine services. Further, it operates CanXChange, a machine-learning powered B2B wholesale and custody technology platform. The company offers its products to cultivators, manufacturers, pharmacies, clinics, and patients under the Breathe Life Science, Dr Watson, Mirai Solution, and Apothecary CBD brands. It sells its products through wholesale, retail, and online. Bioxyne Limited is headquartered in Sydney, Australia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Bioxyne Ltd reported revenue of A$30.4M in FY2025 versus A$2.1M in FY2021, a compound +94.9%/yr. Reported net income was A$4.9M in FY2025.
BXN screens 63% overvalued. Compare with Nestlé S.A →
Peer Group
Packaged Foods · 668 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Packaged Foods median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Packaged Foods stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Nestlé S.A NESN | CHF 79.06 | CHF 57.26 | -28% |
| Danone S.A BN | €65.48 | €48.41 | -26% |
| Nestlé India Limited NESTLEIND | ₹1,478 | ₹251.94 | -83% |
| The Kraft Heinz Company KHC | $24.53 | $24.59 | +0% |
| Foshan Haitian Flavouring and Food Company 603288 | ¥35.05 | ¥21.93 | -37% |
| Inner Mongolia Yili Industrial Group 600887 | ¥25.51 | ¥32.50 | +27% |
| Yihai Kerry Arawana Holdings 300999 | ¥25.28 | ¥9.89 | -61% |
| General Mills, Inc GIS | $38.18 | $28.32 | -26% |
| Wilmar International Limited F34 | 3.64 SGD | 3.89 SGD | +7% |
| McCormick & Company MKCV | $55.65 | $43.29 | -22% |
Compare Bioxyne Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Bioxyne Ltd (BXN) overvalued or undervalued?
What is the fair value of BXN?
What is the quality score of BXN?
What is the revenue of Bioxyne Ltd (BXN)?
What is the net profit margin of BXN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Bioxyne Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.